The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands

被引:33
|
作者
Furtado, Patricia B. [1 ]
Huang, Chen Y. [1 ]
Ihyembe, Demvihin [1 ]
Hammond, Russell A. [2 ]
Marsh, Henry C. [2 ]
Perkins, Stephen J. [1 ]
机构
[1] UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England
[2] AVANT Immunotherapeut, Needham, MA 02494 USA
基金
英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
X-ray scattering; ultracentrifugation; molecular graphics; constrained; modelling; SCR domain;
D O I
10.1016/j.jmb.2007.09.085
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human complement receptor type 1 (CR1, CD35) is a type I membrane-bound glycoprotein that belongs to the regulators of complement activity (RCA) family. The extra-cellular component of CRI is comprised of 30 short complement regulator (SCR) domains, whereas complement receptor type 2 (CR2) has 15 SCR domains and factor H (FH) has 20 SCR domains. The domain arrangement of a soluble form of CRI (sCR1) was studied by X-ray scattering and analytical ultracentrifugation. The radius of gyration R(G) of sCR1 of 13.4(+/- 1.1) nm is not much greater than those for CR2 and FH, and its R(G)/R(0) anisotropy ratio is 3.76, compared to ratios of 3.67 for FH and 4.1 for CR2. Unlike CR2, but similar to FH, two cross-sectional R(G) ranges were identified that gave R(XS) values of 4.7( +/- 0.2) nm and 1.2(+/- 0.7) nm, respectively, showing that the SCR domains adopt a range of conformations including folded-back ones. The distance distribution function NO showed that the most commonly occurring distance in sCR1 is at 11.5 nm. Its maximum length of 55 run is less than double those for CR2 or FH, even though sCR1 has twice the number of SCR domains compared to CR2 Sedimentation equilibrium experiments gave a mean molecular weight of 235 kDa for sCR1. This is consistent with the value of 245 kDa calculated from its composition including 14 N-linked oligosaccharide sites, and confirmed that sCR1 is a monomer in solution. Sedimentation velocity experiments gave a sedimentation coefficient of 5.8 S. From this, the frictional ratio (f/f(0)) of sCR1 was calculated to be 2.29, which is greater than those of 1.96 for CR2 and 1.77 for FH. The constrained scattering modelling of the sCRI solution structure starting from homologous SCR domain structures generated 5000 trial conformationally randomised models, 43 of which gave good scattering fits to show that sCR1 has a partly folded-back structure. We conclude that the inter-SCR linkers show structural features in common with those in FH, but differ from those in CR2, and the SCR arrangement in CR1 will permit C3b or C4b to access all three ligand sites. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:102 / 118
页数:17
相关论文
共 50 条
  • [31] BINDING OF C3B AND C4B BY THE CR-1-LIKE SITE IN MURINE CR-1
    KALLI, KR
    FEARON, DT
    JOURNAL OF IMMUNOLOGY, 1994, 152 (06): : 2899 - 2903
  • [32] Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation
    Mossakowska, D
    Dodd, I
    Pindar, W
    Smith, RAG
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1999, 29 (06) : 1955 - 1965
  • [33] INDUCTION OF IL-1 RELEASE THROUGH STIMULATION OF THE C3B/C4B COMPLEMENT RECEPTOR TYPE ONE (CR-1, CD35) ON HUMAN-MONOCYTES
    BACLE, F
    HAEFFNERCAVAILLON, N
    LAUDE, M
    COUTURIER, C
    KAZATCHKINE, MD
    JOURNAL OF IMMUNOLOGY, 1990, 144 (01): : 147 - 152
  • [34] C3-NEPHRITIC FACTOR PROTECTION OF BOUND C-3 FROM BREAKDOWN BY C3B C4B INACTIVATOR AND THE COMPLEMENT RECEPTOR-CR1
    MOLD, C
    MEDOF, ME
    IMMUNOBIOLOGY, 1983, 164 (3-4) : 278 - 278
  • [35] MONOCLONAL-ANTIBODIES TO THE HUMAN C3B/C4B RECEPTOR (CR-1) ENHANCE SPECIFIC B-CELL DIFFERENTIATION
    WEISS, L
    DELFRAISSY, JF
    VAZQUEZ, A
    WALLON, C
    GALANAUD, P
    KAZATCHKINE, MD
    JOURNAL OF IMMUNOLOGY, 1987, 138 (09): : 2988 - 2993
  • [36] HUMAN-COMPLEMENT C3B/C4B RECEPTOR (CR-1) MESSENGER-RNA POLYMORPHISM THAT CORRELATES WITH THE CR-1 ALLELIC MOLECULAR-WEIGHT POLYMORPHISM
    HOLERS, VM
    CHAPLIN, DD
    LEYKAM, JF
    GRUNER, BA
    KUMAR, V
    ATKINSON, JP
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) : 2459 - 2463
  • [37] HUMAN COMPLEMENT C3B INACTIVATOR - ISOLATION, CHARACTERIZATION, AND DEMONSTRATION OF AN ABSOLUTE REQUIREMENT FOR SERUM-PROTEIN BETA-1H FOR CLEAVAGE OF C3B AND C4B IN SOLUTION
    PANGBURN, MK
    SCHREIBER, RD
    MULLEREBERHARD, HJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 146 (01): : 257 - 270
  • [38] CR-1, THE RECEPTOR FOR THE C3B FRAGMENT OF COMPLEMENT, IN PATHOLOGY
    JOUVIN, MH
    PATHOLOGIE BIOLOGIE, 1988, 36 (04): : 291 - 292
  • [39] ROLE OF THE CR-1 RECEPTOR FOR THE C3B FRAGMENT OF COMPLEMENT
    JOUVIN, MH
    KAZATCHKINE, M
    PRESSE MEDICALE, 1988, 17 (16): : 773 - 775
  • [40] EXPRESSION OF COMPLEMENT C3B C4B RECEPTORS (CR-1) ON ERYTHROCYTES FROM PATIENTS WITH MYASTHENIA-GRAVIS
    VEDELER, CA
    GILHUS, NE
    MATRE, R
    ACTA NEUROLOGICA SCANDINAVICA, 1990, 82 (04): : 259 - 262